These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30893088)

  • 1. Pain and sickle cell disease.
    Aich A; Jones MK; Gupta K
    Curr Opin Hematol; 2019 May; 26(3):131-138. PubMed ID: 30893088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune cell neural interactions and their contributions to sickle cell disease.
    Sagi V; Mittal A; Gupta M; Gupta K
    Neurosci Lett; 2019 Apr; 699():167-171. PubMed ID: 30738871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting pain at its source in sickle cell disease.
    Gupta K; Jahagirdar O; Gupta K
    Am J Physiol Regul Integr Comp Physiol; 2018 Jul; 315(1):R104-R112. PubMed ID: 29590553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting novel mechanisms of pain in sickle cell disease.
    Tran H; Gupta M; Gupta K
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):546-555. PubMed ID: 29222304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast Cell-Mediated Mechanisms of Nociception.
    Aich A; Afrin LB; Gupta K
    Int J Mol Sci; 2015 Dec; 16(12):29069-92. PubMed ID: 26690128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting novel mechanisms of pain in sickle cell disease.
    Tran H; Gupta M; Gupta K
    Blood; 2017 Nov; 130(22):2377-2385. PubMed ID: 29187376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse Models of Pain in Sickle Cell Disease.
    Sagi V; Song-Naba WL; Benson BA; Joshi SS; Gupta K
    Curr Protoc Neurosci; 2018 Oct; 85(1):e54. PubMed ID: 30265442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice.
    Vang D; Paul JA; Nguyen J; Tran H; Vincent L; Yasuda D; Zaveri NT; Gupta K
    Haematologica; 2015 Dec; 100(12):1517-25. PubMed ID: 26294734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.
    Vincent L; Vang D; Nguyen J; Benson B; Lei J; Gupta K
    Haematologica; 2016 May; 101(5):566-77. PubMed ID: 26703965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heme Causes Pain in Sickle Mice
    Lei J; Paul J; Wang Y; Gupta M; Vang D; Thompson S; Jha R; Nguyen J; Valverde Y; Lamarre Y; Jones MK; Gupta K
    Antioxid Redox Signal; 2021 Feb; 34(4):279-293. PubMed ID: 32729340
    [No Abstract]   [Full Text] [Related]  

  • 11. Morphine for the treatment of pain in sickle cell disease.
    Gupta M; Msambichaka L; Ballas SK; Gupta K
    ScientificWorldJournal; 2015; 2015():540154. PubMed ID: 25654130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of Sickle Cell Disease.
    Sundd P; Gladwin MT; Novelli EM
    Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.
    Puri L; Nottage KA; Hankins JS; Anghelescu DL
    Paediatr Drugs; 2018 Feb; 20(1):29-42. PubMed ID: 28853040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive, integrative management of pain for patients with sickle-cell disease.
    Yoon SL; Black S
    J Altern Complement Med; 2006 Dec; 12(10):995-1001. PubMed ID: 17212571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological pain and the neuroimmune interface.
    Grace PM; Hutchinson MR; Maier SF; Watkins LR
    Nat Rev Immunol; 2014 Apr; 14(4):217-31. PubMed ID: 24577438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia.
    DeLeo JA; Tanga FY; Tawfik VL
    Neuroscientist; 2004 Feb; 10(1):40-52. PubMed ID: 14987447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.
    Sagi V; Argueta DA; Kiven S; Gupta K
    Complement Ther Med; 2020 Jun; 51():102394. PubMed ID: 32507420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence.
    Elander J; Lusher J; Bevan D; Telfer P; Burton B
    J Pain Symptom Manage; 2004 Feb; 27(2):156-69. PubMed ID: 15157040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging treatments for vaso-occlusive pain in sickle cell disease.
    Dampier C
    Expert Rev Hematol; 2019 Oct; 12(10):857-872. PubMed ID: 31364883
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.